State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China.
J Ethnopharmacol. 2013 Aug 26;149(1):270-80. doi: 10.1016/j.jep.2013.06.035. Epub 2013 Jun 28.
Huang-Lian-Jie-Du-Decotion (HLJDD, Hwangryun-Hae-Dok-Decotion in Japan), an ancient antipyretic and detoxifying traditional Chinese medicine formula, was reported to have protective effect on ischemic stroke.
To investigate the therapeutic effect of HLJDD on ischemic stroke and explore its mode of action.
A model of ischemic stroke in the rat was established after transient middle cerebral artery occlusion (MCAO) followed by reperfusion. Rats were assigned randomly to groups of control, sham, transient ischemia/reperfusion (I/R), and three treatment groups by HLJDD at 2.5, 5.0, 10.0mg/kg. The neurological deficit, the cerebral infarct size, morphology abnormality, biochemical parameters were examined, and the levels of relevant proteins were determined by immunoblotting analysis to evaluate the protective effects of HLJDD on ischemic stroke and explore the underlying mechanism.
Compared with I/R group, HLJDD significantly ameliorated neurological deficit and histopathology changes, decreased infarct area, and restored the levels of biochemical indicators including nitric oxide (NO), malondialdehyde (MDA), glutathione (GSH), glutathione disulfide (GSSG), total superoxide dismutase (T-SOD), Cu/Zn-SOD, Mn-SOD and glutathione peroxidase (GSH-PX). HLJDD also notably elevated the levels of microtubule-associated protein 1 light chain 3 (LC3), Beclin-1, and other autophagy related genes (Atgs), promoted the activation of extracellular signal-regulated kinases (ERK), protein kinase B (Akt), 3-phosphoinositide-dependent kinase (PDK1), and inhibited the activation of mammalian target of rapamycin (mTOR), c-Jun N-terminal protein kinases (JNK), p38, phosphatase and tensin homolog (PTEN).
HLJDD showed neuroprotective effects on ischemic stroke, at least in part to the induced protective autophagy via the regulation of mitogen-activated protein kinase (MAPK) signals. This Akt-independent protective autophagy is favorable in the treatment of stroke, avoiding unfavorable side-effects associated with the inactivation of Akt. The efficacy of HLJDD on ischemic stroke and its safety warranted by its long-term clinical use in traditional Chinese medicine favored further study to develop HLJDD as an effective therapeutic agent to treat ischemic stroke.
黄连解毒汤(HLJDD,在日本被称为黄莲泻心汤)是一种古老的解热解毒中药方剂,据报道对缺血性中风具有保护作用。
探讨 HLJDD 对缺血性中风的治疗作用,并探讨其作用模式。
采用短暂性大脑中动脉闭塞(MCAO)后再灌注的方法建立大鼠缺血性中风模型。将大鼠随机分为对照组、假手术组、短暂性缺血/再灌注(I/R)组和 HLJDD 三个治疗组,分别以 2.5、5.0、10.0mg/kg 给药。通过神经功能缺损评分、脑梗死面积、形态学异常、生化参数检测和免疫印迹分析测定相关蛋白水平,评价 HLJDD 对缺血性中风的保护作用,并探讨其作用机制。
与 I/R 组相比,HLJDD 明显改善了神经功能缺损和组织病理学改变,降低了梗死面积,恢复了包括一氧化氮(NO)、丙二醛(MDA)、谷胱甘肽(GSH)、谷胱甘肽二硫化物(GSSG)、总超氧化物歧化酶(T-SOD)、Cu/Zn-SOD、Mn-SOD 和谷胱甘肽过氧化物酶(GSH-PX)在内的生化指标水平。HLJDD 还显著提高了微管相关蛋白 1 轻链 3(LC3)、Beclin-1 和其他自噬相关基因(Atgs)的水平,促进了细胞外信号调节激酶(ERK)、蛋白激酶 B(Akt)、3-磷酸肌醇依赖性蛋白激酶(PDK1)的激活,并抑制了雷帕霉素靶蛋白(mTOR)、c-Jun N-末端蛋白激酶(JNK)、p38、磷酸酶和张力蛋白同源物(PTEN)的激活。
HLJDD 对缺血性中风具有神经保护作用,至少部分是通过调节丝裂原活化蛋白激酶(MAPK)信号诱导保护性自噬实现的。这种 Akt 非依赖性的保护性自噬有利于中风的治疗,避免了 Akt 失活相关的不利副作用。HLJDD 在中药临床长期应用中的疗效和安全性为进一步将其开发为治疗缺血性中风的有效治疗药物提供了依据。